NYSE:VNE - Veoneer Stock Price, Forecast & News

Veoneer's stock was trading at $8.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VNE shares have decreased by 25.6% and is now trading at $6.69. View which stocks have been mosted impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veoneer in the last year. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Veoneer.

Veoneer is scheduled to release its next quarterly earnings announcement on Friday, April 24th 2020. View our earnings forecast for Veoneer.

Veoneer Inc (NYSE:VNE) issued its earnings results on Wednesday, February, 5th. The company reported ($0.87) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.11) by $0.24. The business had revenue of $456 million for the quarter, compared to the consensus estimate of $459.61 million. Veoneer had a negative return on equity of 26.44% and a negative net margin of 26.25%. View Veoneer's earnings history.

Veoneer updated its first quarter 2020 Pre-Market earnings guidance on Friday, March, 20th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $350-370 million, compared to the consensus revenue estimate of $390.09 million.

11 equities research analysts have issued 12-month price targets for Veoneer's stock. Their forecasts range from $7.00 to $35.00. On average, they anticipate Veoneer's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 213.9% from the stock's current price. View analysts' price targets for Veoneer.

Headlines about VNE stock have been trending very negative recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Veoneer earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutVeoneer.

Some companies that are related to Veoneer include Dorman Products (DORM), LCI Industries (LCII), Dana (DAN), Gentherm (THRM), Standard Motor Products (SMP), Meritor (MTOR), Adient (ADNT), Delphi Technologies (DLPH), Tower International (TOWR), Stoneridge (SRI), IOCHPE MAXION S/S (IOCJY), American Axle & Manufact. (AXL), Motorcar Parts of America (MPAA), Garrett Motion (GTX) and Tenneco (TEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veoneer investors own include Pfizer (PFE), Constellation Pharmaceuticals (CNST), Gilead Sciences (GILD), Groupon (GRPN), Inovio Pharmaceuticals (INO), Netflix (NFLX), Autoliv (ALV), Franklin Resources (BEN), Canadian Natural Resources (CNQ) and California Resources (CRC).

Veoneer trades on the New York Stock Exchange (NYSE) under the ticker symbol "VNE."

Shares of VNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VNE stock can currently be purchased for approximately $6.69.

Veoneer has a market capitalization of $745.26 million and generates $1.90 billion in revenue each year. The company earns $-500,000,000.00 in net income (profit) each year or ($4.92) on an earnings per share basis. Veoneer employs 8,600 workers across the globe. View additional information about Veoneer.

The official website for Veoneer is http://www.veoneer.com/.

Veoneer's mailing address is KLARABERGSVIADUKTEN 70 SECTION C6 BOX 13089, STOCKHOLM V7, 10302. The company can be reached via phone at 46-8-527-762-00 or via email at [email protected]